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Objective. Anti–tumor necrosis factor (anti-TNF)
agents are successful therapies in rheumatoid arthritis
(RA); however, inadequate response occurs in 30–40%
of patients treated. Knowledge of the genetic factors that
influence response may facilitate personalized therapy.
The purpose of this study was to identify genetic pre-
dictors of response to anti-TNF therapy in RA and to
validate our findings in independent cohorts.
Methods. Data from genome-wide association
(GWA) studies were available from the Wellcome Trust
Case Control Consortium for 566 anti-TNF–treated RA
patients. Multivariate linear regression analysis of
changes in the Disease Activity Score in 28 joints at 6
months was conducted at each single-nucleotide poly-
morphism (SNP) using an additive model. Associated
markers (P <1 0
–3) were genotyped in 2 independent
replication cohorts (n  379 and n  341), and a
combined analysis was performed.
Results. Of 171 successfully genotyped markers
demonstrating association with treatment response in
the GWA data, 7 were corroborated in the combined
analysis. The strongest effect was at rs17301249, map-
ping to the EYA4 gene on chromosome 6: the minor
allele conferred improved response to treatment (coef-
ficient –0.27, P  5.67
–05). The minor allele of
rs1532269, mapping to the PDZD2 gene, was associated
with a reduced treatment response (coefficient 0.20, P 
7.37
–04). The remaining associated SNPs mapped to
intergenic regions on chromosomes 1, 4, 11, and 12.
Conclusion. Using a genome-wide strategy, we
have identified and validated the association of 7 genetic
loci with response to anti-TNF treatment in RA. Addi-
tional confirmation of these findings in further cohorts
will be required.
Rheumatoid arthritis (RA) is a chronic, auto-
immune, inflammatory disease of the synovial joints,
affecting 1% of the Caucasian population (1). Disease
progression leads to joint destruction, resulting in func-
tional disability, and RA is a significant cause of comor-
bidity and mortality.
The mainstay of treatment for RA is disease-
modifying antirheumatic drugs (DMARDs), such as
methotrexate, which aim to control the widespread
inflammation characteristic of the disease. However,
such drugs are often associated with significant side
effects and are not universally effective. In recent years,
the anti–tumor necrosis factor (TNF) biologic drugs,
including etanercept, infliximab, and adalimumab, have
proven highly successful in potently suppressing both
inflammation and joint damage, with 60–70% of patients
responding to these therapies (2,3). However, this means
that a substantial proportion of patients show no re-
sponse or only a limited response, and given their
expense (approximately £10,000 per patient per year in
the UK; similar in other countries), the identification of
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645predictors of response at baseline could be of great
clinical and economic benefit by allowing the targeting
of these therapies to the patients who are most likely to
respond.
Clinical predictors of response, such as concur-
rent methotrexate or nonsteroidal antiinflammatory
drug therapy, functional disability, and smoking habits,
account for only a small proportion of the variance in
treatment response (4,5). Additional factors, such as
genetic and serologic markers, are also likely to influ-
ence response.
Most studies of genetic predictors of anti-TNF
response performed to date have focused on candidate
genes known to play or thought to play a role in
susceptibility to RA, such as the HLA–DRB1 shared
epitope in the HLA region (6). Other studies have
investigated the TNF gene itself (7,8), additional genes
in the TNF signaling pathway (9), and other cytokines
(10). Despite the many studies that have been con-
ducted, no gene that influences anti-TNF response in
RA has been definitively identified and replicated, al-
though evidence for a role of the TNF –308 polymor-
phism is compelling (5). Small sample sizes and a focus
on few variants in a narrow selection of candidate genes
are the most likely explanations for this limited success,
which highlights the need for a new strategy.
Over the last 2–3 years, genome-wide association
(GWA) studies have been highly successful in identify-
ing susceptibility genes in complex diseases. Such studies
aim to interrogate thousands of genetic markers cover-
ing the majority of the whole genome to assess their
relationship to the particular outcome of interest. Thus,
GWA studies take an unbiased view of the whole
genome and therefore have a higher probability of
detecting an association with a genetic marker, providing
that the studies are sufficiently powered.
In 2007, the Wellcome Trust Case Control Con-
sortium (WTCCC) in the UK published the results of a
large collaborative effort aimed at identifying common
susceptibility polymorphisms implicated in 7 complex
diseases (11). A case–control GWA study of 500,000
single-nucleotide polymorphisms (SNPs) was performed
in 3,000 control subjects and in 2,000 patients in each
disease group, one of which was RA. Of the 2,000 RA
cases contributed by our group, 566 were patients re-
ceiving anti-TNF treatment and had available data re-
garding treatment response.
The aims of the current study, therefore, were
first, to identify candidate genetic predictors of response
to anti-TNF therapy from the available GWA data and
second, to validate these findings using independent
cohorts of anti-TNF–treated RA patients.
PATIENTS AND METHODS
Study design. This study used a 3-stage design. In the
first stage, GWA analysis of change in the Disease Activity
Score in 28 joints (DAS28) (12) between baseline and 6
months was undertaken in 566 anti-TNF–treated RA patients
who where included as part of the WTCCC study (stage 1
cohort). In the second stage, markers demonstrating evidence
of association (P  10
–3) in stage 1 were genotyped in an
independent cohort of 410 individuals (stage 2 cohort), and a
meta-analysis of the 2 datasets was performed. In stage 3,
markers for which the association signal was strengthened by
meta-analysis, as compared to the association signal observed
in the stage 1 cohort alone, were investigated in a third cohort
of 364 anti-TNF–treated RA patients (stage 3 cohort), and a
second meta-analysis of all 3 datasets was performed. The
choice of a 3-stage design was pragmatic, since the study is
actively recruiting, and further genotyping/analysis was under-
taken as sufficient additional samples became available for
inclusion.
Patients. The British Society for Rheumatology Bio-
logics Register (BSRBR) was initiated with the aim of assess-
ing the adverse events associated with treatment with the 3
anti-TNF biologic agents. The BSRBR has detailed clinical
and response criteria on 4,000 patients with RA receiving each
drug. Collaborations were established with a subset of the
larger prescribing centers as part of the Biologics in Rheuma-
toid Arthritis Genetics and Genomics Study Syndicate
(BRAGGSS; see Appendix A for the BRAGGSS investigators
and study centers). Blood samples for DNA extraction were
obtained from anti-TNF–treated RA patients who met the
following 3 inclusion criteria: 1) RA confirmed by a physician,
2) currently receiving or about to begin receiving treatment
with 1 of 3 anti-TNF drugs (etanercept, infliximab, or adali-
mumab), and 3) Caucasian origin, thus reducing the potential
for spurious associations arising as a result of population
stratification. Patients were ineligible for this study if they had
stopped treatment during the first 6 months for reasons other
than lack of efficacy.
Marker selection and genotyping. Genotyping of DNA
samples included in the original GWA study of RA was
described in detail in the online methods for the WTCCC
report (11). Briefly, 250 ng of DNA was genotyped using an
Affymetrix GeneChip 500K Mapping Array Set, which inter-
rogates 500,000 SNPs. After quality control measures, a total
of 459,446 SNPs remained available for analysis.
Markers demonstrating a significant association (P 
10
–3) with treatment response in the initial GWA stage of the
study were selected for replication. Markers with minor allele
frequencies of 10% were excluded from further investiga-
tion, as were markers with genotype frequencies that deviated
from Hardy-Weinberg equilibrium at P  10
–3.
To reduce the genotyping burden at the second stage
of the study, linkage disequilibrium between association signals
from the initial stage was analyzed, and tag SNPs demonstrat-
ing correlation (r
2  0.8) with the remaining associated SNPs
were selected for genotyping. These analyses were performed
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GENETIC INVESTIGATION OF ANTI-TNF TREATMENT EFFICACY IN RA 647using Plink statistical software, release v1.07 (online at http://
pngu.mgh.harvard.edu/purcell/plink/).
DNA samples from the patients evaluated in stages 2
and 3 were genotyped using a Sequenom MassArray iPlex
system. In each reaction, 10 ng of DNA was used, and the
protocol was followed according to the manufacturer’s instruc-
tions (www.Sequenom.com).
Quality control measures were used at the genotyping
stages of the study. Samples and SNPs with a genotyping
success rate of  80% were excluded from analyses.
Statistical analysis. Multivariate linear regression ana-
lysis was used to assess the effect of each SNP genotype on
response to treatment, using the absolute change in the DAS28
at 6 months of followup (a continuous variable) as the outcome
measure. Regression analyses were adjusted for covariates
previously identified as being independent predictors of
change in the DAS28: baseline DAS28, Health Assessment
Questionnaire (HAQ) score (13), and concurrent DMARD
therapy. These analyses were performed using Plink statistical
software, release v1.07. In the stage 1 cohort, sex and smok-
ing history were not significantly associated with change in
the DAS28, and serology data (e.g., anti–cyclic citrullinated
peptide antibody and rheumatoid factor) was available for
85% of patients; therefore, these data were not included as
covariates.
To establish a drug type–specific effect at any of the
associated loci, data for all samples were combined, and an
interaction term was fitted between SNP loci and drug type
(i.e., etanercept, infliximab, or adalimumab). These analyses
were performed using Stata statistical software, release 9, 2005
(StataCorp; online at www.stata.com)
Power calculations were performed using Quanto ver-
sion 1.2.3 (online at http://hydra.usc.edu/gxe) under an additive
model for a range of marker allele frequencies.
RESULTS
For stage 1 of the study, the initial GWA, DNA
samples from 566 RA patients receiving anti-TNF treat-
ment were available for study. The initial analysis had
90% power to detect a difference of 0.6 units in the
absolute change in the DAS28 at the significance thresh-
old (P  10
–3) for allele frequencies 15%.
For investigation of association signals arising from
the initial GWA, 410 patients who were also treated with
one of the anti-TNF biologic agents were genotyped.
Genotyping quality control failed in 7 patients, leaving
403 patients, of which 379 had complete information for
analysis. Finally, 364 patients were genotyped in stage 3
of the study. Genotyping quality control failed in 16 of
them, and of the remaining 348 patients, 341 had
sufficient data on baseline covariates and on treatment
response for analysis. Patient characteristics for the 3
cohorts available for analysis are given in Table 1.
Stage 1, initial GWA analysis. Of the 459,446 SNP
markers analyzed, 382 SNPs demonstrated significant
association (P  10
–3) with response to treatment, as
measured by the absolute change in the DAS28 at 6
months. After excluding SNPs with a minor allele fre-
quency of 0.10 and those deviating from Hardy-
Weinberg equilibrium (P  10
–3), 247 SNPs remained for
further investigation. A list of these SNPs and their corre-
sponding P values for the additive model of association are
shown in Supplementary Table 1 (available on the Arthritis
& Rheumatism web site at http://onlinelibrary.wiley.com/
journal/10.1002/(ISSN)1529-0131).
Usingataggingstrategybasedonlinkagedisequili-
brium between associated SNPs (R
2  0.8), the number
of SNPs prioritized for genotyping in the first replication
cohort was reduced from 247 to 183 (Supplementary
Table 1).
Stage 2, first meta-analysis. Of the 183 SNP
markers identified in stage 1, 12 (i.e., rs11254686,
rs11170826, rs10512080, rs10167992, rs9471419,
rs6838850, rs6432150, rs4957798, rs3911167, rs2810034,
rs16892786, and rs12312888) failed to genotype in the
stage 2 cohort, leaving a total of 171 SNPs for meta-ana-
lysis (Supplementary Table 1).
Ten SNP markers (i.e., rs7305646, rs1350948,
rs7962316, rs17301249, rs1532269, rs4694890, rs7070180,
rs12081765, rs1024125, and rs10739625) demonstrated
an improved association signal with the response to
anti-TNF treatment in the meta-analysis of the discovery
and stage 2 cohorts over and above that observed in the
discovery cohort alone (P  0.001) under an additive
model of association (Table 2).
Stage 3, second meta-analysis. To further inves-
tigate the observed associations with treatment re-
sponse, the 10 SNPs were genotyped in a second inde-
pendent cohort of anti-TNF–treated RA patients. Three
SNPs (rs7070180, rs1024125, and rs10739625) failed to
genotype, leaving 7 SNPs for analysis. A second meta-
analysis of these data along with the discovery and stage
2 cohort data for the 7 SNPs was performed. The
association signal for each marker (i.e., rs12081765,
rs1350948, rs1532269, rs17301249, rs4694890, rs7305646,
and rs7962316) remained the same or diminished in
significance in the second meta-analysis, as compared
with that observed in the first meta-analysis (Table 3).
For the SNP markers rs4694890, rs1350948, and
rs7962316, the effect was observed in the opposite
direction in the stage 3 cohort, as compared with the
initial and stage 2 cohorts, suggesting that these associ-
ations may be spurious.
Clinical significance. Taking into account the
clinical and demographic factors previously shown by
our group and others to influence response to anti-TNF
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HAQ score, sex, concurrent DMARD therapy, rheuma-
toid factor positivity, and smoking habits), the variance
in the absolute change in the DAS28 at 6 months of
followup in the combined cohort was 15%. Incorporat-
ing into the model the 7 genetic loci identified by the
current study increased the variance explained to 20%.
When the model was restricted to include only those
SNPs with between-study continuity in the direction
of effect (i.e., rs12081765, rs1532269, rs17301249, and
rs7305646), the variance in response to treatment was
19%.
Each treatment response–associated SNP was
investigated for drug type–specific effects by fitting an
interactive term in the analysis. No statistical correlation
between the type of therapy used and the SNP marker
was observed (data not shown).
DISCUSSION
We performed a multistage comprehensive
GWA study of response to anti-TNF treatment in pa-
tients with RA. In combining the results of the initial
GWA study and 2 independent cohorts, we demon-
strated evidence of association at 7 genetic loci not
previously implicated in response to these drugs, with
the significance of the association increased for markers
rs12081765, rs17301249, and rs7305646 in the second
meta-analysis, as compared to the initial GWA results
(Tables 2 and 3).
Two of the SNP markers map within genes: the
PDZ domain–containing protein 2 (PDZD2) and eyes
absent homolog 4 (EYA4). The SNP marker rs1532269,
which is associated with a reduced response to TNF
blockade, is an intronic polymorphism mapping to the
PDZD2 gene. The SNP resides in a region of linkage
disequilibrium confined to the latter portion of PDZD2
and demonstrates correlation (r
2  0.8) with 5 other
intronic SNPs within PDZD2. The PDZD2 gene has
been reported to influence the secretion of insulin in an
animal model in which pancreatic islet cells of Pdzd2-
deficient mice produce more insulin than do normal
islets and display increased insulin secretion at low
concentrations of glucose (14). Insulin resistance and
elevated insulin levels are features of severe disease in
early RA, if untreated, and are driven primarily by
systemic inflammation (15). In RA, dramatic reductions
Table 3. Genotype and response to treatment association data in the stage 3 cohort for 7 associated SNPs*
SNP Chr.
Position,
bp Genotype
Stage 3 cohort (n  341)
Second meta-analysis,
fixed-effects
Count
Baseline
DAS28,
mean  SD
Change in
DAS28,
mean  SD
Additive model
P
Coefficient
(95% CI) P Coefficient
rs12081765 1 162,073,507 11 95 6.5  0.8 2.6  1.5
12 155 6.6  1.1 2.5  1.4 7.12
01 0.04 (0.16, 0.23) 7.39
04 0.18
22 77 6.5  0.9 2.5  1.4
rs1532269 5 32,054,598 11 142 6.4  1.0 2.5  1.4
12 150 6.7  0.9 2.5  1.4 7.01
01 0.04 (0.17, 0.26) 7.37
04 0.20
22 35 6.6  1.1 2.6  1.4
rs17301249 6 133,654,607 11 219 6.5  1.0 2.5  1.4
12 97 6.5  1.0 2.8  1.4 2.61
01 0.14 (0.39, 0.11) 5.67
05 0.27
22 14 7.0  0.9 2.5  1.5
rs7305646† 12 17,155,604 11 83 6.7  1.0 2.5  1.2
12 162 6.5  1.0 2.4  1.4 2.92
01 0.11 (0.31, 0.09) 1.47
04 0.21
22 82 6.5  0.8 2.7  1.6
rs4694890 4 48,067,195 11 102 6.5  1.0 2.5  1.5
12 153 6.5  1.0 2.7  1.3 3.45
01 0.09 (0.10, 0.29) 6.47
03 0.15
22 74 6.7  0.9 2.4  1.4
rs1350948 11 23,474,981 11 219 6.5  1.0 2.5  1.4
12 103 6.6  1.0 2.6  1.4 2.29
01 0.16 (0.42, 0.10) 8.64
03 0.19
22 9 6.6  0.7 3.1  1.4
rs7962316 12 90,922,423 11 146 6.5  1.0 2.5  1.4
12 124 6.5  0.9 2.5  1.4 1.51
01 0.14 (0.33, 0.05) 2.05
02 0.13
22 57 6.6  1.0 2.8  1.3
* Chr.  chromosome; DAS28  Disease Activity Score in 28 joints; 95% CI  95% confidence interval. 1  major allele, 2  minor allele.
† The genotyping assay for this single-nucleotide polymorphism (SNP) failed in both replication cohorts; therefore, 2 perfect proxies (rs4522221;
r
2  1 [first replication cohort] and rs7133213; r
2  1 [second replication cohort]) were genotyped.
650 PLANT ET ALin serum insulin levels are observed following anti-TNF
treatment (16). Therefore, a potentially interesting con-
nection exists between insulin levels and disease severity
in patients with RA, and this connection may have a
genetic basis.
The EYA4 SNP associated with an improved
treatment response in the current study, rs17301249, is
an intronic variant tagging an additional intronic EYA4
polymorphism (rs9375955) that was associated with re-
sponse to treatment at the initial GWA analysis stage. In
the HapMap CEU (Utah residents with ancestry from
northern and western Europe) data set (release 22), the
two SNPs are strongly correlated with other intronic
EYA4 SNPs and SNPs upstream of the transcription
start site; the region of high linkage disequilibrium does
not stretch to any nearby genes. Mapping to chromo-
some 6q23.2, EYA4 was originally discovered as a co–
transcription factor and is observed to stimulate the
expression of interferon- (IFN) and CXCL10 in re-
sponse to undigested DNA of apoptotic cells (17). Once
engulfed by macrophages, the DNA molecule from dead
cells is digested by the activity of DNase II. Mice that are
deficient in DNase II are prone to developing chronic
arthritis as a result of the production of TNF and IFN
(17). Cross-talk between type I IFN and TNF has
recently been investigated in patients with RA, in whom
elevated expression of type I IFN response genes has
been shown to correlate with a poor clinical response
following TNF blockade (18). The observed genetic
association in the current study could therefore indicate
a link between DNA-induced innate immune responses
and the efficacy of TNF blockade.
Three SNPs (i.e., rs4694890, rs1350948, and
rs7962316) showed an improved association signal in the
first meta-analysis, over and above that seen in the initial
GWA data; however, these SNPs failed to associate with
treatment response in the stage 3 cohort (n  341), and
with the effect observed in the direction opposite that
expected (Tables 2 and 3). The between-cohort differ-
ences in association signals for these loci are likely to be
due to the small sample sizes, and while interpretation of
these data should be treated cautiously, they suggest that
these may be false-positive signals.
Interpreting the validated association signals lo-
cated in intergenic loci on chromosomes 1 (rs12081765),
4 (rs4694890), 11 (rs1350948), and 12 (rs7962316 and
rs7305646) is challenging, since they do not map close to
obvious candidate genes. Nonetheless, we have found
evidence of association with anti-TNF response, and it is
possible to speculate that they represent long-range
regulatory elements for other genes that they may lie
more closely to when the 3-dimensional conformation
rather than the linear DNA sequence is taken into
account. Investigation of chromosomal conformation
will be required to explore this further.
Our study has some limitations that require dis-
cussion. First, in order to avoid false-negative associa-
tions at the initial GWA stage, a relatively lenient
statistical threshold of P  10
–3 was chosen, thus running
the risk of generating a high proportion of false-positive
associations. Our strategy was to validate association
signals rather than imposing a strict level of significance
at the first stage. In the combined analysis of all 3
cohorts by meta-analysis, evidence of association was
increased over that obtained in the initial cohort alone
for 3 of the 7 markers investigated (rs12081765,
rs17301249, and rs7305646). Therefore, it is important
that other researchers in the field also aim to provide
additional verification of our findings in independent
collections of anti-TNF–treated RA patients.
Second, although a powerful means of measuring
treatment response, the DAS28 score has the limitation
that it is a composite score, relying on information about
swollen and tender joint counts, patient-reported gen-
eral health status, and the erythrocyte sedimentation
rate (ESR). Hence, it should not be surprising that
genetic effects influencing this complex phenotype are
likely to be individually modest, as has been found in
most studies of disease susceptibility. Where large effect
sizes have been observed in pharmacogenetic studies,
there is usually a well-defined phenotype (such as a rare
adverse event) or detection of an association with a
biologic marker, such as the influence of genetic varia-
tion in warfarin therapy, as assessed by measurements of
the international normalized ratio. In assessing response
to anti-TNF therapies, therefore, stronger effect sizes
may be seen with individual components of the DAS28
score. For example, the ESR is a biologic marker of
inflammation and is therefore an objective measure that
may provide a more accurate means of assessing treat-
ment response. Future studies will examine genetic
predictors of response using the ESR as the outcome
measure to investigate whether that approach highlights
the same genetic loci or whether the proportion of
signals from the initial phase that are subsequently
validated is higher.
To date, our study, which included 1,285 patients,
is the largest investigation of genetic predictors of
anti-TNF response in RA patients. The sample size used
at the initial phase of the study afforded 90% power to
detect a change in the DAS28 of 0.6 units, representing
a clinically relevant change in disease activity, at allele
GENETIC INVESTIGATION OF ANTI-TNF TREATMENT EFFICACY IN RA 651frequencies 0.15. It is possible that effects conferred by
less frequent alleles were overlooked.
Despite the limitations, 7 loci have been identi-
fied, which, when added into predictive models, substan-
tially increase the variance accounted for over and above
clinical variables alone. The next step will be to further
explore the 7 loci using a fine-mapping strategy to
identify the polymorphism responsible for the effect on
treatment response. This will be particularly challenging
at the intergenic loci identified, since the associated SNP
is often 100 kb from the nearest known gene, or there
are no obvious candidate genes in the region. It is
therefore likely that functional variants with long-range
effects on gene regulation are responsible for the ob-
served associations at these intergenic loci.
In summary, we have performed a multistage
association study of response to anti-TNF treatment in
RA patients and have identified 7 genetic loci that
influence treatment response in our data. As with all
studies of genetic determinants of complex phenotypes,
our findings require validation in independent cohorts.
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